560101-04-4

Upstream product

• 7693-46-1 4-Nitrophenyl chloroformate 
• 560101-02-2 (2-{[hydroxy-(4-hydroxy-phenyl)-acetyl]-methyl-amino}-ethyl)-methyl-carbamic acid tert-butyl ester 
• 1198-84-1 4-hydroxymandelic acid 
• 177587-81-4 bis(1,1-dimethylethyl) [1,2-ethylenediamine]-1,1'-dicarboxylate 

Downstream Products

• 560101-08-8 carbonic acid {[2-(tert-butoxycarbonyl-methyl-amino)-ethyl]-methyl-carbamoyl}-[4-({2-[(3-hydroxy-3-methyl-5-oxo-hexyloxycarbonyl)-methyl-amino]-ethyl}-methyl-carbamoyloxy)-phenyl]-methyl ester 4-nitro-phenyl ester 
• 560101-06-6 (2-{[4-({[2-(tert-butoxycarbonyl-methyl-amino)-ethyl]-methyl-carbamoyl}-hydroxy-methyl)-phenoxycarbonyl]-methyl-amino}-ethyl)-methyl-carbamic acid 3-hydroxy-3-methyl-5-oxo-hexyl ester 

Relevant academic research and scientific papers

A chemical adaptor system designed to link a tumor-targeting device with a prodrug and an enzymatic trigger

Targeting tumors can be achieved by using a novel chemical adaptor system (see picture) comprising, for example, the anticancer drug epotoside, an N-(2-hydroxypropyl) methacrylamide (HPMA) copolymer as the tumor-targeting device, and catalytic antibody 38C2 as the triggering enzyme in a single entity. When the enzyme cleaves the substrate, it triggers a spontaneous reaction that releases the active drug from the targeting moiety.